Trial Profile
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of olopatadine hydrochloride (AL-4943A) Ophthalmic Solution 0.77% Administered Once Daily
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Nov 2017
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary)
- Indications Allergic conjunctivitis
- Focus Adverse reactions; Registrational
- Sponsors Alcon
- 07 Mar 2014 New trial record